Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirellizumab plus chemotherapy with or without low-dose sensitizing radiotherapy as induction before concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma
ChiCTR2500112408Phase 2Not yet recruiting
- Sponsor
- Sichuan Cancer Hospital
- Start
- Nov 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of tislelizumab in nasopharyngeal carcinoma (NPC) (2 arms), sponsored by Sichuan Cancer Hospital. Primary endpoint: Complete response rate after induction therapy. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
tislelizumab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR2500112408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500112408.